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Abstract
Background: Multidrug resistance mediated by the multidrug resistance-associated protein 1
(MRP1) decreases cellular drug accumulation. The exact mechanism of MRP1 involved multidrug
resistance has not been clarified yet, though glutathione (GSH) is likely to have a role for the
resistance to occur. N-acetylcysteine (NAC) is a pro-glutathione drug. DL-Buthionine (S,R)-
sulfoximine (BSO) is an inhibitor of GSH synthesis. The aim of our study was to investigate the
effect of NAC and BSO on MRP1-mediated vincristine resistance in Human Embryonic Kidney
(HEK293) and its MRP1 transfected 293MRP cells. Human Embryonic Kidney (HEK293) cells were
transfected with a plasmid encoding whole MRP1 gene. Both cells were incubated with vincristine
in the presence or absence of NAC and/or BSO. The viability of both cells was determined under
different incubation conditions. GSH, Glutathione S-Transferase (GST) and glutathione peroxidase
(GPx) levels were measured in the cell extracts obtained from both cells incubated with different
drugs.
Results:  N-acetylcysteine increased the resistance of both cells against vincristine and BSO
decreased NAC-enhanced MRP1-mediated vincristine resistance, indicating that induction of
MRP1-mediated vincristine resistance depends on GSH. Vincristine decreased cellular GSH
concentration and increased GPx activity. Glutathione S-Transferase activity was decreased by
NAC.
Conclusion: Our results demonstrate that NAC and BSO have opposite effects in MRP1 mediated
vincristine resistance and BSO seems a promising chemotherapy improving agent in MRP1
overexpressing tumor cells.
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Background
The acquisition of resistance to anticancer agents used in
chemotherapy is the main cause of treatment failure in
malignant disorders, provoking tumours to become resist-
ant during treatment, although they initially respond to it
[1-4]. Resistance of cancer cells to a single drug is usually
accompanied by resistance to other drugs with different
structures and cellular targets [3,4]. Identifying the mech-
anisms leading to intrinsic or acquired multidrug resist-
ance (MDR) is important in developing more effective
therapies. At least, two proteins are well-known for caus-
ing MDR. Both proteins, the MDR1  gene encoded-Pgp
and MRP1 are members of the ATP binding cassette trans-
porter superfamily. Despite their common involvement in
MDR, there are clear differences in function and substrate
specifity of Pgp and MRP1 [5]. Pgp transports neutral, or
positively charged, hydrophobic compounds [5]. In con-
trast, MRP1 extrudes conjugated organic anions from cells
and is known as multispecific aniontransporter (MOAT)
[4,6,7]. The exact mechanism of MRP1 involved multid-
rug resistance remains unknown, although GSH is likely
to have a role for the resistance to occur. Thus, clarifying
the mechanism of action of MRP1 in cell lines ortumors
overexpressing MRP1 and the search for inhibitors of drug
transport can give new insights in future experiments and
therapies.
Multidrug resistance protein (MRP1) mediated drug
resistance occurs against a broad spectrum of natural
product drugs like vincristine, although the mechanisms
have not been exactly understood and it has not been pos-
sible to demonstrate that MRP1 can actively transport
unmodified forms of vincristine [8]. Vincristine is a vinca
alcaloid type drug and a widely used chemotherapeutic
agent for the treatment of acute leukemia and solid
tumors [9]. Efflux of hydrophobic natural product anti-
cancer drugs agents such as vincristine from cells express-
ing MRP1 is thought to require GSH [10,11]. The nature
of the involvement of GSH is not fully clarified, though
co-transport of GSH is now believed to take place
[8,10,12]. GSH is the most abundant non-protein intrac-
ellular thiol containing compound that is a key molecule
in MRP1-mediated MDR [3,13]. It was shown that ATP-
dependent uptake of vincristine by MRP-enriched, inside-
out membrane vesicles could be stimulated by physiolog-
ical concentrations of GSH [14]. It is suggested that
increased MRP1 expression without an increase in GSH
biosynthesis would not cause any drug resistance in
tumor cells, but would result in cell death [15]. GSH con-
jugates with drugs catalyzed by the enzyme GST and
causes their subsequent removal from the cells [15]. BSO
inhibits GSH synthesis by irreversible inhibition of γ -
glutamyl cysteine synthase and has no other known effect
on cells [3,11,16]. N-acetylcysteine is a thiol antioxidant
and cysteine source for GSH synthesis [17]. The study
aimed to define the mechanism of action of vincristine
and the effects of NAC and BSO on MRP1-mediated vinc-
ristine resistance in Human Embryonic Kidney (HEK293)
and its MRP1 transfected 293MRP cells. For this purpose,
HEK293 and 293MRP cells were incubated with vincris-
tine in the presence or absence of NAC and/or BSO. Vinc-
ristine cytotoxicity, cell viability and the effect of
vincristine on cellular GSH levels, GST and GPx enzyme
activities were determined in both cell groups in the pres-
ence or absence of NAC at two different concentrations.
Results
Western Blot analysis using monoclonal QCRL-1 anti-
MRP1 antibody demonstrated MRP1 expression in
293MRP cells, unlike HEK293 cells (Fig 1).
Cytotoxic Activity of Vincristine
The experiments were repeated 3 times and the results
obtained from these repetitions were averaged. The cyto-
toxic effect of different concentrations of vincristine on
HEK293 cells was shown in Figure 2. The lethal concentra-
tion (LD50) of vincristine was found as 0.156 µg/ml on
HEK293 cells using crystal violet method (Fig 2). This
concentration of vincristine was applied for incubation of
the cells.
Effects of NAC on vincristine cytotoxicity
The viability of HEK293 and 293MRP cells treated with
vincristine was significantly lower than the respective
untreated control cells (11.4 ± 2.3% and 52.4 ± 5.2%
respectively, p < 0.5) (Fig 3). 293MRP cells were more
resistant to vincristine than HEK293 cells. The lowest level
in cell viability was observed in HEK293 cells. Both cells
were incubated with 1 or 5 mM NAC in the presence of
vincristine. N-acetylcysteine supplementation at both
concentrations enhanced significantly the resistance of
293MRP and HEK293 cells against vincristine cytotoxicity
Western Blot Detection of MRP1 in Human Embryonal Kid- ney Cell Line Transfected with the MRP1 gene Figure 1
Western Blot Detection of MRP1 in Human Embryonal Kid-
ney Cell Line Transfected with the MRP1 gene.Cancer Cell International 2005, 5:22 http://www.cancerci.com/content/5/1/22
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Cell viability of MRP1 and HEK293 cells against different concentrations of vincristine Figure 2
Cell viability of MRP1 and HEK293 cells against different concentrations of vincristine.
Effect of N-acetylcysteine (NAC) on vincristine cytotoxicity in human embryonic kidney (HEK293) and 293MRP Cells Figure 3
Effect of N-acetylcysteine (NAC) on vincristine cytotoxicity in human embryonic kidney (HEK293) and 293MRP Cells. * p < 
0.05 vs untreated control HEK293 cells ** p < 0.05 vs untreated control 293MRP cells *** p < 0.05 vs HEK293 cells treated 
with Vinc † p < 0.05 vs HEK293 cells treated with Vinc + 1 mM NAC †† p < 0.05 vs HEK293 cells treated with Vinc + 5 mM 
NAC ††† p < 0.05 vs 293MRP cells treated with Vinc ‡ p < 0.05 vs 293MRP cells treated with Vinc + 1 mM NAC.Cancer Cell International 2005, 5:22 http://www.cancerci.com/content/5/1/22
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compared to their respective untreated control cells (p <
0.05). The viability of HEK293 cells increased signifi-
cantly (p < 0.05) from 11.4 ± 2.3% to 31.1 ± 4.1% with 1
mM NAC and to 37.5 ± 4.7% with 5 mM NAC. The viabil-
ity of 293MRP cells increased significantly (p < 0.05) from
52.4 ± 5.2% to 57.2 ± 5.4% with 1 mM NAC and to 70.1
± 6.2% with 5 mM NAC. There was no significant differ-
ence between the viability of HEK293 cells treated with
two different concentrations of NAC, but 5 mM NAC was
more effective in 293MRP cells compared to the 1 mM
NAC (p < 0.05).
Effect of BSO on vincristine cytotoxicity and survival 
promoting action of NAC
Cells were pretreated with 100 µM BSO for 24 hour before
drug treatments. The viability of 293MRP and HEK293
cells pretreated with BSO was not different significantly
(85 ± 5.3% and 93 ± 6.1%, respectively. p > 0.05) (Fig 4).
After inhibition of GSH synthesis with BSO, 293MRP cells
lost their vincristine resistance significantly from 52.4 ±
5.2% to 19.0 ± 1.9% (p < 0.05) (Fig 4). Pretreatment with
BSO didnot affect the viability of HEK293 cells treated
with vincristine (11.4 ± 2.3% vs 10.2 ± 1.2%). N-acetyl-
cysteine at both concentrations increased significantly the
viability of 293 MRP cells pretreated with BSO against vin-
cristine (from 19.0 ± 1.9% to 33.6 ± 5.4 with 1 mM NAC
and to 40.5 ± 6.2% with 5 mM NAC). Similar increase was
observed in HEK293 cells under the same conditions
(from 10.2 ± 1.2% to 19.2 ± 2.4 with 1 mM NAC and to
29.9 ± 3.2% with 5 mM NAC). Pretreatment with BSO
antagonized partly the increases in the viability of both
cells caused by treatment with NAC compared to the
increases caused by NAC alone (Fig 3 and Fig 4). In other
words, NAC increased less the viability of both cells pre-
treated with BSO than the cells treated with only NAC
against vincristine.
Effect of vincristine and NAC on cellular GSH 
concentrations
Cellular GSH levels were measured after 24 and 48 hour
vincristine treatments in the presence or absence of NAC
at two different concentrations. Cellular GSH concentra-
tions were not different in untreated control HEK293 and
293MRP cells (80.2 ± 4.6 µg mg-1 protein and 84.6 ± 4.9
µg mg-1 protein, respectively) (Fig 5). Glutathione levels
decreased not significantly after 24- and 48-h vincristine
treatments in HEK293 cells from 80.2 ± 4.6 µg mg-1 pro-
tein to 75.9 ± 3.8 µg mg-1 protein and to 72.2 ± 3.5 µg mg-
1 protein (p > 0.05) and in 293MRP cells from 86 ± 4.9 µg
mg-1 protein to 72.4 ± 3.4 µg mg-1 protein and to 64.9 ±
Effect of DL-Buthionine (S,R)-sulfoximine (BSO) on vincristine cytotoxicity and survival promoting effect of N-acetylcysteine  (NAC) in human embryonic kidney (HEK293) and 293MRP Cells Figure 4
Effect of DL-Buthionine (S,R)-sulfoximine (BSO) on vincristine cytotoxicity and survival promoting effect of N-acetylcysteine 
(NAC) in human embryonic kidney (HEK293) and 293MRP Cells. * p < 0.05 vs HEK293 cells pretreated with BSO ** p < 0.05 
vs 293MRP cells pretreated with BSO *** p < 0.05 vs HEK293 cells treated with Vinc † p < 0.05 vs 293MRP cells treated with 
Vinc †† p < 0.05 vs HEK293 cells treated with BSO+Vinc and HEK293 cells treated with Vinc ††† p < 0.05 vs 293MRP cells 
treated with BSO+Vinc ‡ p < 0.05 vs 293MRP cells treated with BSO+Vinc+1 mM NAC ‡‡ p < 0.05 vs HEK293 cells treated 
with BSO+Vinc+1 mM NAC.Cancer Cell International 2005, 5:22 http://www.cancerci.com/content/5/1/22
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3.2 µg mg-1 protein (p < 0.05). N-acetylcysteine at both
concentrations caused a significant increase in GSH con-
centrations in both cells treated with vincristine for both
incubation times, in comparison to untreated control cell
lines and cells treated with only vincristine (p < 0.05) (Fig
5).
Effect of vincristine and NAC on the activity of cellular 
Glutathione S-Transferase and Glutathione Peroxidase
Glutathione S-Transferase activity in both untreated con-
trol cell lines was not significantly different. 48 hour, but
not 24 hour incubation with vincristine significantly
increased the GST activity in both cell lines comparing to
the corresponding untreated control cells (Fig 6). N-ace-
tylcysteine (1 mM) for 48 hour caused a significant
decrease in GST activity in 293MRP and HEK293 cells
compared with nontreated control cells and cells treated
with only vincristine for both incubation times. 5 mM
NAC at both incubation times caused a significant
decrease in the GST activity in both cell lines compared to
nontreated control cells, cells treated with vincristine only
and cells treated with vincristine + NAC (1 mM) for both
incubation times (Fig 6).
There was no significant difference in GPx activity
between HEK293 and 293MRP cells (2.4 ± 0.2 IU mg-1
protein and 2.2 ± 0.1 IU mg-1 protein, respectively) (Fig
7). Non-significant increases in GPx activity were
observed after vincristine treatment for both incubation
times in HEK293 (2.8 ± 0.3 IU mg-1 protein for 24 h vinc-
ristine incubation and 3.1 ± 0.3 IU mg-1 protein for 48 h
vincristine incubation) and 293MRP cells (2.6 ± 0.2 IU
mg-1 protein for 24 h vincristine incubation and 3.0 ± 0.3
IU mg-1 protein for 48 h vincristine incubation) compared
to untreated control cells (p > 0.05). N-acetylcysteine (1
mM) incubation for 24 and 48 hours increased GPx activ-
ity in both cell lines compared to untreated control cells.
5 mM NAC incubation for 24 and 48 hours increased the
GPx activity significantly in HEK293 and 293MRP cells
compared to the other cell groups (p < 0.05) (Fig 7).
Discussion
In our experiments, the viability of MRP1 transfected cells
(293MRP) treated with vincristine was higher than
human embryonic kidney (HEK293). Our results are in
accordance with O'Brien and co-workers who reported
that MRP1 confers resistance to doxorubicin, etoposide,
and vincristine in NIH 3T3 fibroblast cell line [18]. Our
experiments with N-acetylcysteine (NAC) and DL-Buthio-
nine (S,R)-sulfoximine (BSO) showed that MRP1 medi-
ated vincristine resistance largely depends on GSH and
this is in accordance with previous data [3,18,19]. N-ace-
tylcysteine supplementation at both concentrations
increased the survival rate of vincristine treated HEK293
and 293MRP cells which had increased GSH levels con-
firming that the viability depends on the level of GSH (Fig
3 and Fig 4). After inhibition of GSH synthesis with BSO,
293MRP cells lost their vincristine resistance (Fig 4).
Similar results were described previously in different cell
lines overexpressing MRP1 [3,16].
Effects of Vincristine and N-acetylcysteine (NAC) on intracellular glutathione (GSH) levels in human embryonic kidney  (HEK293) and 293MRP Cells Figure 5
Effects of Vincristine and N-acetylcysteine (NAC) on intracellular glutathione (GSH) levels in human embryonic kidney 
(HEK293) and 293MRP Cells. * p < 0.05 vs untreated control 293MRP cells ** p < 0.05 vs untreated control HEK293 cells and 
HEK293 cells treated with Vinc for 24 and 48 hour *** p < 0.05 vs untreated control 293MRP cells and 293MRP cells treated 
with Vinc for 24 and 48 hour † p < 0.05 vs HEK293 cells treated with Vinc+1 mM NAC for 24 and 48 hour †† p < 0.05 vs 
293MRP cells treated with Vinc+1 mM NAC for 24 and 48 hour.Cancer Cell International 2005, 5:22 http://www.cancerci.com/content/5/1/22
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We compared the viability of both cells treated with vinc-
ristine and NAC in the presence and absence of BSO. N-
acetylcysteine at both concentrations increased signifi-
cantly the viability of 293MRP and HEK293 cells pre-
treated with BSO against vincristine, but these increases
were lower in comparison to the corresponding cells
Effects of Vincristine and N-acetylcysteine (NAC) on Glutathione S-transferase Activity (GST) in human embryonic kidney  (HEK293) and 293MRP Cells Figure 6
Effects of Vincristine and N-acetylcysteine (NAC) on Glutathione S-transferase Activity (GST) in human embryonic kidney 
(HEK293) and 293MRP Cells. * p < 0.05 vs untreated control HEK293 cells ** p < 0.05 vs untreated control 293MRP cells *** 
p < 0.05 vs untreated control HEK293 cells and HEK293 cells treated with Vinc for 24 and 48 hour † p < 0.05 vs untreated 
control 293MRP cells and 293MRP cells treated with Vinc for 24 and 48 hour †† p < 0.05 vs untreated control HEK293 cells 
and HEK293 cells treated with Vinc and HEK293 cells treated with Vinc+1 mM NAC for 24 and 48 hour ††† p < 0.05 vs 
untreated control 293MRP cells and 293MRP cells treated with Vinc and 293MRP cells treated with Vinc+1 mM NAC for 24 
and 48 hour.
Effects of Vincristineand N-acetylcysteine (NAC) on Glutathione Peroxidase (GPx) Activity in human embryonic kidney  (HEK293) and 293MRP Cells Figure 7
Effects of Vincristineand N-acetylcysteine (NAC) on Glutathione Peroxidase (GPx) Activity in human embryonic kidney 
(HEK293) and 293MRP Cells. * p < 0.05 vs untreated control HEK293 cells ** p < 0.05 vs untreated control 293MRP cells *** 
p < 0.05 vs untreated control HEK293 cells and HEK293 cells treated with Vinc and HEK293 cells treated with Vinc+1 mM 
NAC for 24 and 48 hour † p < 0.05 vs untreated control 293MRP cells and 293MRP cells treated with Vinc and 293MRP cells 
treated with Vinc+1 mM NAC for 24 and 48 hour.Cancer Cell International 2005, 5:22 http://www.cancerci.com/content/5/1/22
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untreated with BSO (Fig 3 and Fig 4). Pretreatment with
BSO antagonized partly the increases in the viability of
both cells caused by treatment with NAC compared to the
increases caused by NAC alone. In other words, NAC
increased less the viability of both cells pretreated with
BSO than the cells treated with only NAC against vincris-
tine. This might be explained that BSO counterbalances
the effect of NAC as a precursor of GSH. This is another
proof that survival promoting action of NAC depends on
GSH synthesis and is in accordance with our previous
findings with doxorubicin [1].
In our experiments, cellular GSH concentration decreased
after vincristine treatment which might be due to GSH
efflux (Fig 5). Enhanced GSH efflux has been reported in
MRP1 expressing cells and this enhanced efflux can be
inhibited by indomethacin and probenecid [10]. They
suggested that changes in the concentrations of GSH and
its oxidised form GS-SG inside cells may each influence
MRP1-mediated anion transport. Furthermore, hypoxia
or oxidative stress may cause depletion of glutathione
(GSH). Increased oxidative stress has been reported to
associate tumorigenesis [20,21] and this may play a role
in GSH depletion [22,23]. which in turn may affect efflux
of drugs. The higher GPx activity in vincristine treated cells
might be a compensatory effect of cells against depletion
of GSH (Fig 6).
It has been hypothesized that vincristine resistance of
myeloblasts is related to its degradation by myeloperoxi-
dase (MPO) [9]. Myeloperoxidase (MPO) catalyzes the
formation of HOCl from H2O2 and chloride ion. It was
shown oxidation by HOCl is the final step in vincristine
degradation in both a cell free system and in cultures
leukemic cell lines. Oxidation of anti-neoplastic drugs
may cause a reduction in efficacy or an increase in toxicity.
This could lead to a decrease in the therapeutic index.
Inhibition of MPO in these different disease states could
eliminate this intra- and extracellular oxidation pathway
and could effectively increase the therapeutic index.
The identification of MRP1 as an important glutathione-
conjugate efflux pump raises the possibility that MRP1
and GST may act in synergy to confer cellular resistance to
some of these compounds [3,14,24,25]. It is not clear yet
if glutathione is either co-transported as a GS-conjugate
with vincristine or activates MRP1 for vincristine transport
[4]. Studies so far showed conjugation with GSH and
extrusion are not the major pathway [4]. Co-expression
with MRP1 of any of the human GST isozymes A1-1, M1-
1, or P1-1 failed to augment MRP1-associated resistance
to drugs including doxorubicin, vincristine, etoposide,
and mitoxantrone [4,24]. This might be an evidence that
vincristine is not conjugated with GSH, but co-trans-
ported with GSH in MRP1 mediated drug resistance.
In our study, NAC supplementation decreased GST activ-
ity level in both cell lines (Fig 7). This might be explained
that NAC may spontaneously form conjugates with vinc-
ristine, therefore decreasing the need for GST activity for
conjugation. Although, it is not clear whether NAC
spontaneously conjugates with vincristine, it is known
that mercapturic acids (N-acetylcysteine S-conjugates) are
spontaneously formed, released into the circulation and
delivered to the kidney for excretion in urine [26-28].
Similarly, Weigand et al reported attenuation of GST activ-
ity after NAC supplementation [29].
Conclusion
Our results demonstrate that NAC enhances MRP1-medi-
ated vincristine resistance and this effect depends on GSH
synthesis. DL-Buthionine (S,R)-sulfoximine seems a
promising chemotherapy improving agent in MRP1 over-
expressing tumor cells. This finding might be relevant and




Dulbeccos' Modified Eagles' Medium (DMEM), NAC,
BSO, geneticin, Feotal Bovine Serum (FBS), and other
chemicals were purchased from Sigma-Aldrich Corp. St.
Louis, MO, USA. Vincristine was obtained from Oncology
Department of Akdeniz University Hospital. The plasmid
(pcDNA3.1/MRPK) encoding the whole MRP1 gene was
kindly provided by Dr. Susan Cole from Oueen's Univer-
sity, Ontario Canada. Protein Assay Kit was purchased
from Bio-Rad Laboratories Ltd., Herts, UK. Monoclonal
anti-MRP1 QCRL-1 antibody was obtained from Cento-
cor Inc., Malvern, PA, USA. Horseradish peroxidase (HRP)
conjugated seconder goat-anti mouse antibody was pur-
chased from Santa-Cruz Biotechnology Inc., Santa Cruz,
CA, USA.
Cell lines
Human embryonic kidney cell line, HEK293, was grown
in DMEM, supplemented with 10% heat inactivated FBS,
2 mM L-glutamin, and 1% antibiotic-antimycotic solu-
tion. Cell cultures were kept at 37°C in a humid atmos-
phere containing 5% CO2.
Transfection
Cells (1 × 106 cells in 100 mm dish) were transfected with
the plasmid (pcDNA3.1/MRPK) encoding the whole
MRP1 gene. The transfection was made according to the
calcium phosphate transfection method [30]. Sixteen
hours after the transfection, the cells were feeded with
DMEM supplemented with 400 µg/ml geneticin.Cancer Cell International 2005, 5:22 http://www.cancerci.com/content/5/1/22
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Preparation of Membrane Enriched Fractions and 
Immunoblotting
For immunoblotting of the 293MRP and HEK293 cells,
membrane enriched fractions were prepared according to
Grant et al [31]. Briefly, cell pellet was resuspended in the
collection buffer (10 mM Tris-HCL, pH 7.4, 10 mM KCl,
1.5 mM MgCl2 and protease inhibitors), homogenized on
ice in a Potter-Elvejhem tissue homogenizer. The intact
cells and nuclei were removed by centrifugation at 800 g
at +4°C, and the supernatant was further centrifuged at
100 000 g at +4°C for 20 minutes to prepare the mem-
brane enriched fractions. The pellet was resuspended in
buffer (10 mM Tris-HCl pH 7.4, 125 mM sucrose, and
protease inhibitors). The protein suspension was mixed
with solubilizing buffer (4 M urea, 0.5% Sodiumdodecyl-
sulphate (SDS), and 50 mM dithiotreitol) and equal
amounts of proteins were subjected to SDS-PAGE (SDS-
Polyacrylamide gel electrophoresis) on 7%
polyacrylamide gels, then transferred onto nitrocellulose
sheet for overnight at 40 volt, and analysed by immunob-
lotting with anti-MRP1 monoclonal QCRL-1 antibody.
Cell Viability Assays
Cell viability was assayed using the crystal violet method
[32]. 3 × 104 cells were seeded in a 96 well microplate.
After 24 hours, cells were incubated with 0.06–1000 µg/
ml vincristine for 72 hours. LD50 for vincristine was deter-
mined to be 0.156 µg/ml and this dose of vincristine was
used in the rest of the experiments. Both HEK293 and
293MRP cells were incubated with vincristine (0.156 µg/
ml) in the presence or absence of NAC (1 and 5 mM) for
72 hours at 37°C in a humid atmosphere containing 5%
CO2. At the end of incubation period, the medium was
replaced by 0.5% crystal-violet (w/v; in 50% methanol)
solution. Plates were incubated for 10 min at room tem-
perature, washed with water and adsorbed dye was eluted
out with Na-citrate (0.1 M Na-citrate in 50% ethanol, pH
4.2). Absorbance, which was proportional to cell viability,
was measured at a wavelength of 600 nm. Cell viability
was monitored as the percentage of viable cells comparing
to control, untreated cells. For BSO experiments, cells
were pretreated with 100 µM BSO for 24 hours before
incubating them with vincristine with or without NAC for
72 hours as described above.
Preparation of Cell Extract for GSH and Enzyme 
Measurements
Cell extracts were prepared as described by Bravard et al
with a slight modification [33]. 106 cells were seeded in a
cell culture dish and incubated for 24 hours. After incuba-
tion with vincristine in the presence or absence of NAC for
24 or 48 hours, medium was discharged and cells were
washed with phosphate buffered saline (PBS), collected in
potassium phosphate buffer (50 mM, pH 7.4) with cell
scraper and repeatedly freezed and thawed in liquid nitro-
gen for four times, and then centrifuged at 10 000 g for 10
minutes at 4°C. The supernatant was used for enzyme
activities and GSH measurements. Protein concentrations
were determined using Bio-Rad protein assay kit. All
measurements were adjusted by dividing with the protein
content of each sample.
Reduced Glutathione Assay
Cellular GSH concentrations were determined as
described by Virgil et al [34]. Briefly, the supernatant was
deproteinized and GSH content was monitored spectro-
photometrically with 5-5' dithiobis(2-nitrobenzoic acid)
(DTNB) at a wavelength of 412 nm. The GSH concentra-
tion was evaluated using a standart curve of known
amounts of GSH. Results are expressed as µg/mg protein.
Glutathione S-Transferase Activity Assay
Glutathione S-Transferase (GST) activity was measured at
340 nm wavelength in the presence of 1-cloro-2,4-dini-
trobenzene (CDNB), GSH and sodium phosphate buffer
(pH 6.5) at 30°C for 6 minutes [33,35]. Results are
expressed as ∆ OD / mg protein.
Glutathione Peroxidase Activity Assay
Glutathione Peroxidase (GPx) activity was determined
using a modification of the method of Paglia and Valen-
tine [36]. In a cuvette kept at 37°C, GPx activity was mon-
itored at 340 nm by the absorbance of nicotinamide
adenine dinucleotide phosphate (NADPH) for 3 minutes
in the presence of glutathione reductase (0.5 IU), EDTA
(0.3 mM) and t-buthyl hydroperoxide (0.4 mM). Results
are expressed as IU/mg protein.
Statistical Analysis
Statistical analysis was performed using Anova test with
SPSS packed program for Windows version 10.0 (SPSS
Inc., Chicago, IL, USA). All the experiments were repeated
three times. Mean values and standard deviations (mean
± S.D.) were calculated for every variable in each cell
group and were compared between the groups. p < 0.05
was selected as statistically significant.
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